DRUG
Linaclotide Acetate
Oral, once daily
Status
Completed
Phase
Phase 2
Enrollment
420
Locations
85
Results
Posted
Publications
2
Study summary
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
Interventions
DRUG
Oral, once daily
DRUG
Oral, once daily
Timeline
First posted
Apr 16, 2007
Study start
Apr 2007
Primary completion
Feb 2008
Study completion
Apr 2008
Results posted
Jan 30, 2013
Registry updated
Feb 4, 2013
Outcomes
Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period
Time frame · Change from Baseline to Week 12
The change in the weekly normalized CSBM Rate during Weeks 1 through 12 of the Treatment Period from the weekly normalized CSBM Rate obtained during the Pretreatment Period. The CSBM rate was normalized based on the number of CSBMs occurring in that week, adjusting for differences in the duration of the week and black-out periods (time not covered due to a missed IVRS call) versus 7x24 hours.
CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)
Time frame · Change from Baseline to Week 12
For each week of the Treatment and Posttreatment Periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥ 4 days of IVRS questions, 2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from the baseline weekly CSBM rate.
Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period
Time frame · Change from Baseline to Week 12
SBMs were measured daily during the treatment period by patient calls to the IVRS.
Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period
Time frame · Change from Baseline to Week 12
Stool consistency analyses were performed using the 7-point Bristol Stool Form Scale (BSFS), whereby a score of 1 = separate hard lumps like nuts (difficult to pass); 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = watery, no solid pieces (entirely liquid).
Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period
Time frame · Change from Baseline to Week 12
Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.
Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period
Time frame · Change from Baseline to Week 12
Patients provided a weekly assessment of Degree of Relief of IBS Symptoms using a 7-point balanced scale (1=completely relieved, 2=considerably relieved, 3=somewhat relieved, 4=unchanged, 5=somewhat worse, 6=considerably worse, 7=as bad as I can imagine).
Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period
Time frame · Change from Baseline to Week 12
During the study, patients provided their self assessment of abdominal pain using a 5-point ordinal scale (1=none, 2=mild, 3=moderate, 4=severe, 5=very severe
Eligibility
Inclusion Criteria: * Must not be pregnant or breastfeeding and agree to use birth control; * Completion of a negative colonoscopy as per American Gastroenterology Association (AGA) criteria and no clinically-significant laboratory or physical examination findings; * Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria; * Demonstrates English fluency and has access to a touch-tone telephone. Exclusion Criteria: * Recent history of mushy or watery stools; * Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study; * Clinically-significant alarm symptoms; * Secondary causes of constipation or evacuation disorders; * Surgery to the gastrointestinal tract; * Usage of prohibited medications.
Study locations
Canada · United States. Showing up to 24 locations stored in the fast local snapshot.
Microbia Investigational Site
Huntsville, Alabama, United States
Microbia Investigational Site
Chandler, Arizona, United States
Microbia Investigational Site
Tuscon, Arizona, United States
Microbia Investigational Site
Sherwood, Arkansas, United States
Microbia Investigational Site
Anaheim, California, United States
Microbia Investigational Site
Garden Grove, California, United States
Microbia Investigational Site
Sacramento, California, United States
Microbia Investigational Site
San Diego, California, United States
Microbia Investigational Site
Bristol, Connecticut, United States
Microbia Investigational Site
Boynton Beach, Florida, United States
Microbia Investigational Site
Dunedin, Florida, United States
Microbia Investigational Site
Largo, Florida, United States
Microbia Investigational Site
Ocala, Florida, United States
Microbia Investigational Site
Port Orange, Florida, United States
Microbia Investigational Site
Stuart, Florida, United States
Microbia Investigational Site
Tampa, Florida, United States
Microbia Investigational Site
Stockbridge, Georgia, United States
Microbia Investigational Site
Libertyville, Illinois, United States
Microbia Investigational Site
Peoria, Illinois, United States
Microbia Investigational Site
Clive, Iowa, United States
Microbia Investigational Site
Davenport, Iowa, United States
Microbia Investigational Site
Mission, Kansas, United States
Microbia Investigational Site
Shawnee, Kansas, United States
Microbia Investigational Site
Baton Rouge, Louisiana, United States
Publications
Related trials
Mayo Clinic · Irritable Bowel Syndrome With Constipation
Not applicable
Recruiting
65
2026-07
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · Colorectal Adenoma · Stage 0 Colorectal Cancer AJCC v8
Phase 2
Active, not recruiting
150
2026-07
AbbVie · Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Phase 3
Completed
123
2026-05
University of Nottingham · Cystic Fibrosis (CF)
Early Phase 1
Recruiting
26
2026-05
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Texas Tech University Health Sciences Center, El Paso · Chronic Constipation · Diabete Mellitus
Phase 4
Active, not recruiting
23
2026-04
Md Mehedi Shahriar · Chronic Idiopathic Constipation · Irritable Bowel Syndrome (IBS-C)
Phase 4
Not yet recruiting
90
2026-02
University of Florida · Patients Scheduled for Colonoscopy
Phase 1 / Phase 2
Recruiting
10
2026-01
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.